Issuing the 2.4 mg pen for titration bypasses critical safety measures, removes structured oversight, and places undue risk on both the patients health and the prescribers professional standing
Week-by-Week Dosing The FDA-approved titration schedule is: weeks 1 through 4 at 0.25 mg, weeks 5 through 8 at 0.5 mg, weeks 9 through 12 at 1.0 mg, weeks 13 through 16 at 1.7 mg, and maintenance at 2.4 mg from week 17 onward [1]
Both semaglutide and tirzepatide commonly have gastrointestinal side effects, such as: Nausea Vomiting Diarrhea Stomach pains However, you may be more likely to have differences in the prevalence of effects like constipation and acid reflux if taking semaglutide
Ferrara G, Gianotti R, Cavicchini S, Salviato T, Zalaudek I, Argenziano G